Table 3.
Annual and total sensitivity profiles based on antibiotic sensitivity trials of Proteus mirabilis isolates from urinary calculus patients during the 2019–2021 study period (%).
| Antibiotic | 2019 (n = 101) | 2020 (n = 112) | 2021 (n = 104) | 2019–2021 (n = 317) | p value |
|---|---|---|---|---|---|
| Meropenem | 99 (98.0) | 110 (98.2) | 102 (98.1) | 311 (98.1) | 0.994 |
| Imipenem | 96 (95.1) | 108 (96.4) | 101 (97.1) | 305 (96.2) | 0.733 |
| Levofloxacin | 69 (68.3) | 57 (50.8) | 57 (54.8) | 183 (57.7) | 0.028 |
| Cefuroxime | 59 (58.4) | 59 (52.7) | 43 (41.4) | 161 (50.8) | 0.045 |
| Cefoxitin | 84 (83.2) | 99 (88.4) | 88 (84.6) | 271 (85.5) | 0.532 |
| Ceftazidime | 85 (84.2) | 102 (91.1) | 89 (85.6) | 276 (87.1) | 0.278 |
| Ceftriaxone | 66 (65.4) | 73 (65.2) | 57 (54.8) | 196 (61.8) | 0.198 |
| Cefoperazone/Sulbactam | 97 (96.0) | 106 (94.6) | 101 (97.1) | 304 (95.9) | 0.655 |
| Cefepime | 85 (84.2) | 95 (84.8) | 87 (83.7) | 267 (84.2) | 0.972 |
| Amikacin | 100 (98.6) | 112 (100) | 102 (98.1) | 314 (99.1) | 0.345 |
| Piperacillin/Tazobactam | 88 (87.1) | 97 (86.6) | 93 (89.4) | 278 (87.7) | 0.802 |
| Sulfamethoxazole | 32 (31.7) | 43 (38.4) | 32 (30.8) | 107 (33.8) | 0.430 |